Copyright (c) 2024 European Atherosclerosis Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
- Articles
-
Published: August 31, 2024
Abstract
The focus of this review are the novel and future approaches to reduce the cardiovascular (CV) residual risk by reducing the apoB-containing lipoproteins levels. We assume that in the clinical practice a combination therapy based on the use of high intensity statins, ezetimibe, bempedoic acid, mAbs anti PCSK9 or Inclisiran may reduce most of the cardiovascular risk associated with the apoB containing lipoproteins and may contribute to achieve the LDL-Cholesterol (LDL-C) goal in the majority of individuals at high and very high risk. However we can assume that a proportion of well treated patients will develop new cardiovascular events. Many factors such as the genetic background, the pre-existing burden of disease and the residual risk attributable to triglycerides, inflammation, coagulation and platelets may explain this recurrence of events. We discuss some novel options to reduce the residual risk due to the two main apoB-containing lipoproteins, LDL-C and Lp(a), that are:
-the newest-generation CETP inhibitor, Obicetrapib; the oral PCSK9 inhibition; the novel approaches to reduce Lp(a) plasma levels (antisense oligonucleotides-ASO; rna interfering-Sirna; assembly inhibition-; the PCSK9 gene editing.
Article Metrics Graph
References
- Nurmohamed NS, Ditmarsch M, Kastelein JJP. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents? Cardiovasc Res 2022; 118:2919-31. https://doi.org/10.1093/cvr/cvab350
- Rehman WU, Yarkoni M, Ilyas MA, et al. Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. J Cardiovasc Dev Dis 2024; 11:152. https://doi.org/10.3390/jcdd11050152
- Kuhnast S, van der Tuin SJ, van der Hoorn JW, et al. Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin. Eur Heart J 2015; 36:39-48. https://doi.org/10.1093/eurheartj/ehu319
- Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012; 380:572-80. https://doi.org/10.1016/S0140-6736(12)60312-2
- Kastelein JJP, Hsieh A, Dicklin MR, et al. Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments. Curr Atheroscler Rep 2024; 26:35-44. https://doi.org/10.1007/s11883-023-01184-1
- Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376:1713-22. https://doi.org/10.1056/NEJMoa1615664
- Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379:2097-107. https://doi.org/10.1056/NEJMoa1801174
- Schonck WAM, Stroes ESG, Hovingh GK, Reeskamp LF. Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature. Drugs 2024; 84:165-78. https://doi.org/10.1007/s40265-024-01995-9
- Tsimikas S. Lipoprotein(a) in the Year 2024: A Look Back and a Look Ahead. Arterioscler Thromb Vasc Biol 2024; 44:1485-90. https://doi.org/10.1161/ATVBAHA.124.319483
- Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med 2020; 382:244-55. https://doi.org/10.1056/NEJMoa1905239
- Malick WA, Goonewardena SN, Koenig W, Rosenson RS. Clinical Trial Design for Lipoprotein(a)-Lowering Therapies: JACC Focus Seminar 2/3. J Am Coll Cardiol 2023; 81:1633-45. https://doi.org/10.1016/j.jacc.2023.02.033
- O'Donoghue ML, JA GL, Knusel B, et al. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE). Am Heart J 2022; 251:61-9. https://doi.org/10.1016/j.ahj.2022.05.004
- Nissen SE, Linnebjerg H, Shen X, et al. Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial. JAMA 2023; 330:2075-83. https://doi.org/10.1001/jama.2023.21835
- Agarwala A, Asim R, Ballantyne CM. Oral PCSK9 Inhibitors. Curr Atheroscler Rep 2024; 26:147-52. https://doi.org/10.1007/s11883-024-01199-2
- Hoekstra M, Van Eck M. Gene Editing for the Treatment of Hypercholesterolemia. Curr Atheroscler Rep 2024; 26:139-46. https://doi.org/10.1007/s11883-024-01198-3
- Musunuru K, Chadwick AC, Mizoguchi T, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 2021; 593:429-34. https://doi.org/10.1038/s41586-021-03534-y